|||
Altamitage was founded by Markus Dahlem. Markus has extensive experience in digital health. His first business plan, based on his PhD findings, was on mobile telemedical diagnostics (2003).
In 2016, he founded the university spin-off Newsenselab, maker of M-sense, a migraine-focused prescription digital therapeutic (DiGA), which had over 11,000 prescriptions during its provisional listing and the highest re-prescription rates among DiGAs. 
As CEO of Newsenselab, Markus secured a key collaboration with a top-ten pharmaceutical company and explored additional partnerships with firms developing specialty drugs and OTC generics. He also negotiated a distribution partnership for M-sense with a pharmaceutical company and co-founded DiGA info GmbH & Co. KG alongside 4 other DiGA companies: Selfapy, Vivira, Adhere, and Mementor (acquired by ResMed). Beyond the migraine space, he consulted with pharmaceutical companies on the DiGA process and its business opportunities.
Newsenselab Timeline
In 2023, Markus was appointed VP of Science at Click Therapeutics, where he oversaw Discovery, Translational and Clinical Science in both internal development and pharma partnerships. His responsibilities include R&D in neurocognitive brain trainings and neuromodulatory brain entrainment, using data-driven methods to de-risk early phase clinical trials by creating virtual populations for treatment testing and digital twins to manage long-term patient journeys across multiple therapeutic areas, including
Through oircd extensive network in the digital health and pharmaceutical industries, I can assemble a team of experts in Regulatory, Market Access, Clinical Science, ClinOps, Clinical Development, and more—tailored to your project needs. Feel free to ask for more details or discuss your specific requirements.
